Evidence of measurable or evaluable non-measurable disease per RECIST, v1.1
Measurable or non-measurable, but evaluable disease using RECIST v1.1
Patients must have measurable or evaluable disease per RECIST 1.1 criteria
PART I: participants are required to have only evaluable disease (disease that is visible on imaging studies but does not meet RECIST criteria for measurable disease)
One or more measurable or nonmeasurable evaluable lesions per RECIST 1.1.
Patients must have measurable or evaluable disease as defined per the RECIST v1.1 except patients with mCRPC.
Patients in the dose escalation phase of the study must have measurable or evaluable disease according to RECIST 1.1 criteria
Patients must have measurable or evaluable disease per RECIST 1.1 criteria
Measurable or evaluable disease by RECIST v1.1
Evaluable disease per RECIST 1.1
Evaluable/measurable disease by RECIST
Radiologically measurable and clinically evaluable disease as per RECIST v1.1
Evaluable or measurable disease as defined by RECIST v1.1 may be enrolled in the dose escalation part; for the dose confirmation part, subjects must have measurable disease by RECIST v1.1 or biomarker for response.
Patient with a TP53wt locally advanced or metastatic solid malignancy and with measurable or non-measurable (but evaluable) disease as determined by RECIST 1.1 criteria.
Patients must have measurable or evaluable advanced and/or metastatic disease by RECIST 1.1.
Must have evaluable or measurable disease per RECIST 1.1
Evaluable disease by RECIST v1.1.
Confirmed diagnosis of one of the following, and must be measurable or evaluable per RECIST 1.1 (solid tumors) or Lugano (NHL):
Patients must have measurable or non-measurable disease that is evaluable per RECIST 1.1;
Phase 1: Participants must have either measurable or evaluable disease as per RECIST 1.1.
Must be determined to have metastatic or unresectable disease, as determined by treating physician; (must have at least evaluable disease, but does not need to be measurable disease by RECIST 1.1)
Evaluable or measurable disease based on RECIST 1.1 (50)
Have measurable or evaluable disease based on RECIST 1.1
Measurable and/or evaluable disease as per the RECIST criteria version (v) 1.1
Evaluable disease: 1. During Part 1, evaluable disease is required; measurable disease per RECIST v1.1 is recommended but not required, 2. Subjects enrolled in Part 2 must demonstrate measurable disease per the disease-specific criteria.
Measurable or evaluable disease by RECIST v1.1 (not required for the cPoP study)
Must have evaluable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan, according to RECIST 1.1 (subjects with measurable disease per RECIST 1.1 or radiographically visible and evaluable disease). Subjects with only ascites or pleural effusion are excluded.
Measurable or evaluable disease; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1, with radiologic scans within 28 days of day 1, cycle 1; evaluable disease must include bone metastases (pleural effusions and ascites are not considered evaluable for this study)
Have evaluable disease by RECIST 1.1 and PCWG2 criteria
CA-125 only disease without RECIST 1.1 measurable or otherwise evaluable disease
Measurable disease by RECIST or evaluable disease (e.g., bone metastasis, or lesions which do not fulfill RECIST criteria for metastatic disease)
Has evaluable or measurable disease by RECIST v1.1 criteria
At least one measurable/evaluable lesion by RECIST v1.1
Measurable or evaluable disease per RECIST v1.1
Patient has evaluable disease by RECIST v1.1 (Appendix 3).
Existence of measurable or evaluable disease (as per RECIST 1.1 criteria).
Measurable or evaluable disease according to RECIST v1.1.
In Stage 1, evaluable disease per RECIST 1.1. In Stage 2, measurable disease.
Must have baseline measurable or evaluable disease per RECIST
Have measurable and/or evaluable disease by RECIST 1.1
Triple negative breast cancer patients: participants may have either measurable disease via RECIST 1.1 criteria or evaluable disease
Participants must have measurable disease that is evaluable as per RECIST v1.1
Subjects with solid tumors, with the exception of CRPC, must demonstrate measurable disease, per RECIST v1.1. NOTE: Subjects with NMC that do not meet the RECIST v1.1 criteria for measurable disease, but have evaluable disease may be considered for enrollment after discussion with the GSK medical monitor..
Measurable disease via RECIST v1.1 or non-measurable, evaluable disease with at least one evaluable bone lesion via RECIST v1.1
The subject has measurable disease or nonmeasurable, evaluable disease per RECIST 1.1. (NOTE: pleural effusions, ascites or other third fluid space are not evaluable diseases per RECIST 1.1).
Participants must have measurable disease by RECIST v1.1 or non-measurable, evaluable disease with atleast one evaluable bone lesion by RECIST v1.1 based on radiologic scans within 28 days of Day 1 of Cycle 1
Have measurable and/or evaluable disease based on RECIST 1.1.
Measurable or evaluable disease by RECIST 1.1
Measurable or evaluable non-measurable disease as assessed by the investigator according to RECIST v1.1 criteria
Evaluable disease as determined by RECIST 1.1
Subjects must have either measurable disease or bone-only non-measurable disease, evaluable according to RECIST 1.1
Evaluable or measurable disease, as assessed by RECIST v1.1
3. Evaluable disease, or measurable disease as assessed by RECIST version 1.1.
Measurable disease according to RECIST Version 1.1 or non-measurable evaluable disease
Evaluable or measurable disease per RECIST v1.1
Radiologically measurable and clinically evaluable disease as per RECIST v1.1
Meaurable or evaluable extra-cranial disease as defined by RECIST v 1.1
Evaluable or measurable disease per RECIST v1.1
Evaluable or measurable disease per RECIST v1.1
Measurable or evaluable disease by RECIST 1.1
Evaluable or measurable disease per RECIST v1.1
Evaluable or measurable disease per RECIST v1.1
Evaluable or measurable disease per RECIST v1.1
Patients must have presence of at least 1 lesion that is measurable or evaluable using RECIST v1.1.
Subject must have evaluable disease as per RECIST criteria.
Measurable disease or non-measurable but evaluable disease, according to the RECIST v1.1; Participants with peritoneal disease would generally be regarded as having evaluable disease and allowed to enter the trial
At least one measurable lesion and/or non-measurable disease evaluable according to RECIST v1.1 criteria
Measurable disease per RECIST 1.1 criteria. Subjects with non-measurable, but evaluable disease are also eligible for Part 1 of the study.
Measurable or evaluable (non-measurable) disease per RECIST guidelines version 1.1.
Measurable disease per RECIST guidelines (subjects with non-measurable, but evaluable disease are also eligible for the dose escalation portion of the study)
Evaluable disease or disease measurable per RECIST
Evaluable or measurable disease per RECIST, Version 1.1
Patient must be evaluable using RECIST 1.1 criteria
Evaluable disease or disease measurable per RECIST 1.1
